Cancer-directed surgery in malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication

Abstract

Malignant pleural mesothelioma (MPM) is a primary solid malignancy related to inhalational asbestos exposure. Despite advances in therapy, MPM remains challenging to treat with a post-treatment survival of only 15% at 5-year. In recent years, extra-pleural pneumonectomy has decreased in popularity due to a high morbidity rate and mortality compared to pleurectomy/decortication and other therapeutic alternatives. In this review, we will discuss both procedures, outcomes, ongoing studies, and the roles of surgery in the future treatment of this disease.

Keywords

Surgery for malignant pleural mesothelioma / extrapleural pneumonectomy / pleurectomy/decortication / recurrence perioperative mortality

References

[1] Sugarbaker DJ,Chirieac LR.Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.Eur J Cardiothorac Surg2011;40:298-303

[2] Sugarbaker DJ,Bueno R.Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.J Thorac Cardiovasc Surg2004;128:138-46

[3] Berzenji L.Multimodality treatment of malignant pleural mesothelioma.F1000Res2018;7:1681 PMCID:PMC6198256

[4] van Gerwen M, Wolf A, Liu B, Flores R, Taioli E. Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma.J Surg Oncol2018;118:1178-87

[5] Wolf AS.Updates in staging and management of malignant pleural mesothelioma.Surg Oncol Clin N Am2020;29:603-12

[6] Rice D,Pass H.International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest GroupRecommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.J Thorac Oncol2011;6:1304-12

[7] Taioli E,Camacho-Rivera M.Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients.PLoS One2015;10:e0145039 PMCID:PMC4682765

[8] Taioli E,Moline JM,Flores RM.Frequency of surgery in black patients with malignant pleural mesothelioma.Dis Markers2015;2015:282145 PMCID:PMC4430630

[9] Flores RM,Donington JS.Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.J Thorac Oncol2010;5:1649-54

[10] Hasegawa S.Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.Gen Thorac Cardiovasc Surg2014;62:516-21 PMCID:PMC4153961

[11] Ricciardi S,Zirafa CC.Surgery for malignant pleural mesothelioma: an international guidelines review.J Thorac Dis2018;10:S285-92 PMCID:PMC5830571

[12] Bovolato P,Billè A.Does surgery improve survival of patients with malignant pleural mesothelioma?.J Thorac Oncol2014;9:390-6

[13] Flores RM,Seshan VE.Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.J Thorac Cardiovasc Surg2008;135:620-6, 626.e1-3

[14] Raskin J,Cornelissen R,van Schil PEY.A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).Transl Lung Cancer Res2018;7:593-8 PMCID:PMC6204421

[15] Batirel HF,Caglar HB.Trimodality treatment of malignant pleural mesothelioma.J Thorac Oncol2008;3:499-504

[16] Flores RM.Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.Semin Thorac Cardiovasc Surg2009;21:149-53

[17] Sarot IA.Extrapleural pneumonectomy and pleurectomy in pulmonary tuberculosis.Thorax1949;4:173-223 PMCID:PMC1018307

[18] Butchart EG,Barnsley WC.Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.Thorax1976;31:15-24 PMCID:PMC470356

[19] Flores RM,Rosenzweig KE.Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.J Thorac Oncol2006;1:289-95

[20] Yan TD,Tin MM.Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.J Thorac Cardiovasc Surg2009;138:619-24

[21] Sugarbaker DJ,Jaklitsch MT.Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.J Thorac Cardiovasc Surg1999;117:54-65

[22] Weder W,Taverna C.Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.J Clin Oncol2004;22:3451-7

[23] Weder W,Bernhard J.Swiss Group for Clinical Cancer ResearchMulticenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.Ann Oncol2007;18:1196-202

[24] Cho BCJ,Bradbury PA.Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.Lancet Oncol2021;22:190-7

[25] Martini N,Beattie EJ.Indications for pleurectomy in malignant effusion.Cancer1975;35:734-8

[26] Wanebo HJ,Melamed MR,Beattie EJ.Pleural mesothelioma.Cancer1976;38:2481-8

[27] Marulli G,Fontana P.Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes?.Eur J Cardiothorac Surg2017;52:63-9

[28] Bölükbas S,Eberlein M,Fisseler-Eckhoff A.Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy.Lung Cancer2011;71:75-81

[29] Lapidot M,Mazzola E.Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients.Ann Surg2020;

[30] Nakamura A,Hashimoto M.Clinical outcomes with recurrence after pleurectomy/decortication for malignant pleural mesothelioma.Ann Thorac Surg2020;109:1537-43

[31] Sharkey AJ,Tenconi S,Waller DA.Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.Interact Cardiovasc Thorac Surg2017;25:696-702

[32] Teh E,Tan C.A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.J R Soc Med2011;104:69-80 PMCID:PMC3031645

[33] Duranti L,Bertolaccini L.Extra-pleural pneumonectomy.J Thorac Dis2019;11:1022-30 PMCID:PMC6462700

[34] Treasure T,Waller D.Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.Lancet Oncol2011;12:763-72 PMCID:PMC3148430

[35] Okada M,Ohbayashi C,Soejima T.Radical surgery for malignant pleural mesothelioma: results and prognosis.Interact Cardiovasc Thorac Surg2008;7:102-6

[36] Luckraz H,Patel N,Gibbs AR.Three decades of experience in the surgical multi-modality management of pleural mesothelioma.Eur J Cardiothorac Surg2010;37:552-6

[37] Cao C,Park J,Pataky KA.A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.Lung Cancer2014;83:240-5

[38] Taioli E,Flores RM.Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.Ann Thorac Surg2015;99:472-80

[39] Aziz T.The management of malignant pleural mesothelioma; single centre experience in 10 years.Eur J Cardiothorac Surg2002;22:298-305

[40] Magouliotis DE,Athanassiadi K.Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.Gen Thorac Cardiovasc Surg2019;67:312-20

[41] Bölükbas S,Schirren J.Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma.J Thorac Oncol2012;7:900-5

[42] Batirel HF,Caglar HB.Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.J Thorac Cardiovasc Surg2018;155:2724-33

[43] Lim E,Edwards J.MARS 2 TrialistsMesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma.BMJ Open2020;10:e038892 PMCID:PMC7467531

[44] Baldini EH,Strauss GM.Patterns of failure after trimodality therapy for malignant pleural mesothelioma.Ann Thorac Surg1997;63:334-8

[45] Manegold C,Gatzemeier U.Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.Ann Oncol2005;16:923-7

[46] Jassem J,Santoro A.Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.J Clin Oncol2008;26:1698-704

[47] Wolf A,Baldini EH. Patterns of recurrence following pleurectomy/decortication for malignant pleural mesothelioma. In: 11th International Conference of the International Mesothelioma Interest Group. Boston, MA, USA, December 28, 2012.

[48] Weder W,Baas P.The MARS feasibility trial: conclusions not supported by data.Lancet Oncol2011;12:1093-4

[49] Scherpereel A,Baas P.European Respiratory Society, European Society of Thoracic Surgeons[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].Zhongguo Fei Ai Za Zhi2010;13:C23-45 PMCID:PMC6134413

[50] Gupta V,Krug L.Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.Int J Radiat Oncol Biol Phys2005;63:1045-52

[51] Allen AM,Jänne PA.Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.Int J Radiat Oncol Biol Phys2006;65:640-5

[52] Rimner A,Gomez DR.Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma.J Clin Oncol2016;34:2761-8 PMCID:PMC5019761

[53] Stahel RA,Xyrafas A.Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.Lancet Oncol2015;16:1651-8

[54] Minatel E,Polesel J.Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.Lung Cancer2014;83:78-82